Repligen (RGEN) News Today

Repligen (NASDAQ:RGEN) Shares Up 7.3%

Bessemer Group Inc. decreased its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 8.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 305,136 shares of the biotechnology company's stock after sell

Repligen (NASDAQ:RGEN) will be releasing earnings before the market opens on Tuesday, July 30, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=332912)

Westfield Capital Management Co. LP lessened its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 20.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 235,310 shares of the biotechnology company's s

Repligen Co. (NASDAQ:RGEN - Get Free Report) has received an average recommendation of "Moderate Buy" from the ten research firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to

Repligen Co. (NASDAQ:RGEN - Free Report) - Equities researchers at Leerink Partnrs issued their FY2026 EPS estimates for shares of Repligen in a research report issued on Thursday, July 18th. Leerink Partnrs analyst P. Souda anticipates that the biotechnology company will post earnings per share

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lessened its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 11.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 292,740 shares of the biotechnology company's stock after selli

Swiss National Bank reduced its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 4.1% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 158,800 shares of the biotechnology company's stock after selling 6

Sei Investments Co. lowered its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 15.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 218,714 shares of the biotechnology company's stock after sell

TimesSquare Capital Management LLC lowered its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 5.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 194,073 shares of the biotechnol

Capstone Investment Advisors LLC trimmed its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 100.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,831 shares of the biotechnology compan

Daiwa Securities Group Inc. increased its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 243.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,319 shares of the biote

Norden Group LLC boosted its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 1,711.6% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 38,805 shares of the biotechnology co

Allspring Global Investments Holdings LLC lifted its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 21.7% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 335,836 shares of the biotechnology company's st

Artemis Investment Management LLP lifted its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 33.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 167,813 shares of the biotechnology company's stock after buying an

Congress Asset Management Co. MA boosted its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 14.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 88,013 shares of the biotechnology

Vanguard Group Inc. boosted its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 0.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,078,294 shares of the biotechnology company's stock after buying an additional 33,404 shares dur

Repligen (NASDAQ:RGEN) Stock Price Down 6.7%

Goldman Sachs Group Inc. reduced its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 12.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 263,474 shares of the biotechnology company's stock after s

Wellington Management Group LLP lessened its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 21.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,101,497 shares of the biotechnology company's stock after selling 295,113 shares during the quarter. Welling

Congress Asset Management Co. MA raised its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 220.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 76,800 shares of the biotechnology company's stock after purchasi

Repligen (NASDAQ:RGEN) Sees Large Volume Increase

Repligen (NASDAQ:RGEN) Shares Gap Down to $142.87

Harding Loevner LP reduced its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 1.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 716,299 shares of the biotechnology company's stock after selling

Iron Triangle Partners LP acquired a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 82,537 shares of the biotechnology company's stock, valued at approximat

Sei Investments Co. grew its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 2.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 258,941 shares of the biotechnology company's stock after acqu

KBC Group NV decreased its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 60.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,167 shares of the biotechnology company's stock after selling 12,336

Public Employees Retirement Association of Colorado boosted its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 448.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 112,863 shares of

Rhenman & Partners Asset Management AB acquired a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 10,000 shares of the biotechnology company's stock, valued at ap

Stephens Investment Management Group LLC cut its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 3.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 486,798 shares of the biotechnology company's sto

Eagle Asset Management Inc. trimmed its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 17.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 280,056 shares of the biotechnology company's stock after selling 59,933 shares duri

Evoke Wealth LLC acquired a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 10,873 shares of the biotechnology company's stock, valued at approximately $1,955,000. A number of other hedg

Norges Bank acquired a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 268,121 shares of the biotechnology company's stock, valued at approximately $48,208,000. Norge

Dimensional Fund Advisors LP grew its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 5.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 301,968 shares of the biotechnology company's stock after purchasi

Artisan Partners Limited Partnership cut its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 2.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,522,743 shares of the biotechnolo

Westfield Capital Management Co. LP grew its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 20.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 294,222 shares of the biotechnology company's stock after purchasing an additional 49,72

Repligen Co. (NASDAQ:RGEN - Free Report) - Equities research analysts at Zacks Research raised their FY2024 earnings estimates for shares of Repligen in a research note issued on Tuesday, May 21st. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earning